Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Phase 2 trials showed up to 24% body weight reduction at the highest dose, and Phase 3 data from the TRIUMPH program pushed that number even higher, reaching 28.7% in participants with obesity and knee osteoarthritis
These improvements correlated with increased follicular copper levels and enhanced keratinocyte proliferation
Finally, after it has been proven that your B12 levels have returned to a stable state the frequency of administration will be reduced to just one shot each month
Currently, no adverse drug interactions have been reported with BPC-157
(ref) Gwyer D, Wragg NM, Wilson SL
Its role lies in genomic maintenance and early-stage risk reduction, not tumor eradication
